About Milestone Pharmaceuticals Inc.
https://www.milestonepharma.comMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
CEO
Joseph G. Oliveto
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:6.98M
Value:$14.16M
PROPEL BIO MANAGEMENT, LLC
Shares:5.12M
Value:$10.4M
BLACKROCK INC.
Shares:4.97M
Value:$10.09M
Summary
Showing Top 3 of 70
About Milestone Pharmaceuticals Inc.
https://www.milestonepharma.comMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $11.88M ▼ | $-11.92M ▲ | 0% | $-0.12 ▲ | $-11M ▲ |
| Q2-2025 | $0 | $12.53M ▼ | $-12.97M ▲ | 0% | $-0.2 ▲ | $-11.99M ▲ |
| Q1-2025 | $0 | $20.52M ▲ | $-20.76M ▼ | 0% | $-0.31 ▼ | $-19.8M ▼ |
| Q4-2024 | $0 | $11.85M ▲ | $-12.36M ▼ | 0% | $-0.2 ▼ | $-10.94M ▼ |
| Q3-2024 | $0 | $9.62M | $-9.44M | 0% | $-0.14 | $-8.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $82.58M ▲ | $87.75M ▲ | $67.25M ▲ | $20.5M ▲ |
| Q2-2025 | $43.42M ▼ | $47.42M ▼ | $65.16M ▼ | $-17.75M ▼ |
| Q1-2025 | $55.96M ▼ | $61.88M ▼ | $68.01M ▲ | $-6.12M ▼ |
| Q4-2024 | $69.69M ▼ | $75.5M ▼ | $62.35M ▲ | $13.15M ▼ |
| Q3-2024 | $76.42M | $82.71M | $58.69M | $24.01M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.92M ▲ | $-9.82M ▲ | $-35.65M ▼ | $49.66M ▲ | $4.19M ▲ | $-9.82M ▲ |
| Q2-2025 | $-12.97M ▲ | $-12.57M ▲ | $9.94M ▼ | $36K ▼ | $-2.59M ▼ | $-12.58M ▲ |
| Q1-2025 | $-20.76M ▼ | $-13.95M ▼ | $33.58M ▲ | $140K ▲ | $19.77M ▲ | $-13.96M ▼ |
| Q4-2024 | $-12.36M ▼ | $-6.84M ▲ | $19.33M ▲ | $24K ▼ | $12.52M ▲ | $-6.87M ▲ |
| Q3-2024 | $-9.44M | $-7.02M | $6.48M | $74K | $-463K | $-7.02M |
CEO
Joseph G. Oliveto
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:6.98M
Value:$14.16M
PROPEL BIO MANAGEMENT, LLC
Shares:5.12M
Value:$10.4M
BLACKROCK INC.
Shares:4.97M
Value:$10.09M
Summary
Showing Top 3 of 70